3rd generation glp 1 agonist Mazdutide vs retatrutide: dual meets triple agonist in the next-gen weight loss showdown GLP-1 agonists and changes in

54,55 Cardiovascular outcomes The EMPA-REG OUTCOME study by Zinman et al was designed specifically to evaluate the effect of empagliflozin in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD)

Thus, following the example of cancer, drug therapy could precede bariatric surgery in order to render it safer and more feasible, but could also follow if the results are not satisfactory

GLP-1RAs mimic GLP-1 and have primarily been used for glycemic control in type 2 diabetes and for weight reduction in obese patients (8,9)

The researchers said future randomised clinical trials would be needed to test whether GLP-1 receptor agonists could safely and effectively support breast cancer care in defined patient groups

Side effects and tolerability: Nausea, vomiting, or digestive issues sometimes lead patients to stop treatment

Many patients use these drugs for weight management rather than diabetes, and these medications may not be captured in routine medication reconciliation if patients do not volunteer the information